# MDT Discussion Log — 2026-01-21_07-14-45
Generated automatically by MDT Pipeline.



## CASE (structured JSON)

```
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["白紫+卡铂"]},"BIOMARKERS":{"AFP":"<0.91 ng/ml (2022-10-12)","CA125":"933.00 U/ml (2022-12-29)","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging","DIAGNOSIS":{"components":["High-grade adenocarcinoma involving full-thickness intestinal wall","Lymph node metastasis (4/15)","Peritoneal/rectal/vaginal involvement described"],"histology":"透明细胞癌; 肠壁全层见高级别腺癌","laterality":"Unknown","primary":"卵巢癌复发","site":"Ovary"},"HRD":"Unknown","INITIAL_TREATMENT":"Unknown","LINE_OF_THERAPY":[{"cycles":"6","end_date":"2022-08-17","intent":"Unknown","line":"1L","regimen":"白紫+卡铂","start_date":"Unknown"}],"MAINTENANCE":"Unknown","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Unknown","regimens":[],"start_date":"Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"56","PLATINUM_HISTORY":[{"PFI_days":"56","end_date":"2022-08-17","evidence":"Rise in CA125/CA19-9 on 2022-10-12","evidence_type":"Biochemical","first_relapse_date":"2022-10-12","line":"1L","start_date":"Unknown","status":"Resistant"}],"PLATINUM_PFI_CURRENT":"56","PLATINUM_STATUS":"Resistant","PLATINUM_STATUS_CURRENT":"Resistant","RELAPSE":"Yes","RELAPSE_DATE":{"date":"2022-10-12","evidence":"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence","type":"Biochemical"},"SCENE":"Platinum_resistant_relapse","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2022-03-28","performed":"Yes","procedure":"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]},"VISIT_DATE":"2023-01-03","first_relapse_date":"2022-10-12","last_platinum_end_date":"2022-08-17"},"LAB_TRENDS":{"labs":[{"analyte":"CA125","history":[{"date":"2022-08-15","flag":"Unknown","value":"14.90"},{"date":"2022-10-12","flag":"↑","value":"89.60"},{"date":"2022-11-17","flag":"↑","value":"403"},{"date":"2022-12-29","flag":"↑","value":"933.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"933.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"CA19-9","history":[{"date":"2022-08-15","flag":"Unknown","value":"7.16"},{"date":"2022-10-12","flag":"↑","value":"77.20"},{"date":"2022-12-29","flag":"↑","value":"229.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"229.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"HE4","history":[{"date":"2022-08-15","flag":"↑","value":"87.90"},{"date":"2022-10-12","flag":"Unknown","value":"59.70"},{"date":"2022-12-29","flag":"↑","value":"111.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"111.00"},"reference_range":"Unknown","unit":"pmol/L"},{"analyte":"AFP","history":[{"date":"2022-10-12","flag":"Unknown","value":"<0.91"}],"latest":{"date":"2022-10-12","flag":"Unknown","value":"<0.91"},"reference_range":"Unknown","unit":"ng/ml"}],"milestones":[{"date":"2022-03-28","description":"Primary cytoreductive surgery performed","type":"Surgery"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂","type":"ChemoEnd"},{"date":"2022-10-12","description":"Biochemical relapse with rising tumor markers","type":"Relapse"}]},"MED_ONC":{"current_regimen":{"cycle_info":"6 cycles of 白紫+卡铂, last 2022-08-17","last_admin_date":"2022-08-17","name":"Unknown"},"genetic_testing":{"germline":[],"somatic":[]},"monitoring_points":[],"planned_next_regimen":"Unknown","prior_systemic_therapies":["白紫+卡铂"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["Tumor size ~7x4x2.5 cm","Bilateral margins negative","Pericolic lymph nodes 4/15 positive","One tumor nodule (posterior bladder)"],"date":"2022-03-28","diagnosis":"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma","grade":"High-grade","ihc":[{"marker":"MLH1","result":"+"},{"marker":"MSH6","result":"+"},{"marker":"MSH2","result":"+"},{"marker":"PMS2","result":"+"},{"marker":"ER","result":"partial+"},{"marker":"PR","result":"few weak+"},{"marker":"P53","result":"+/-"},{"marker":"WT1","result":"-"},{"marker":"Ki-67","result":"60%+"},{"marker":"HNF1B","result":"+"},{"marker":"NapsinA","result":"focal+"},{"marker":"P16","result":"+"},{"marker":"PAX8","result":"+"},{"marker":"SALL4","result":"-"},{"marker":"ZBTB16","result":"-"}],"involvement_sites":["Rectosigmoid colon","Left retroperitoneum","Vagina","Pericolic lymph nodes","Posterior bladder nodule"],"laterality":"Unknown","molecular":[],"raw_text":"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）","sample_type":"Surgical resection","site":"Partial rectosigmoid + left retroperitoneal tumor + partial vagina","tumor_size":"7 x 4 x 2.5 cm","uncertainty_or_missing":["BRCA/HRD testing not reported"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Pelvis"],"date":"2022-10-24","findings":["Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules"],"impression":"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases","modality":"MRI","trend_vs_prior":"Unknown"},{"anatomic_sites":["Liver"],"date":"2022-10-25","findings":["Multiple intrahepatic nodules, some new compared to prior"],"impression":"Probable metastases in liver","modality":"CT","trend_vs_prior":"Worse"},{"anatomic_sites":["Pelvis; sacrum; right iliac bone"],"date":"2022-12-30","findings":["Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar"],"impression":"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible","modality":"MRI","trend_vs_prior":"Worse"},{"anatomic_sites":["Liver; spleen"],"date":"2022-12-30","findings":["Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct"],"impression":"Progression of hepatic metastases","modality":"CT","trend_vs_prior":"Worse"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]}}
```


## FINAL MDT OUTPUT

```
# Final Assessment
Recurrent platinum-resistant (PFI 56 days) ovarian clear cell carcinoma with hepatic, presacral, and bone metastases; BRCA1/2 negative, HRD negative [@OH2203828 | Genomics], limiting PARPi utility; moderate anemia requires correction before systemic therapy.

# Core Treatment Strategy
- **Initiate non-platinum systemic regimen** per platinum-resistant status classification [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
- **Correct anemia (Hgb 74 g/L)** [@20230103|5600862 | LAB] with transfusion before chemotherapy initiation
- **Obtain PET-CT** for complete metabolic staging to guide treatment planning [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
- **Evaluate clinical trial eligibility** for BL-B01D1 study in recurrent gynecologic malignancies [@trial | 350]; confirm ECOG status and organ function

# Change Triggers
- If MSI-high/TMB-high detected, consider adding checkpoint inhibitor to treatment strategy [@pubmed | 35096598]
- If bone lesions show high fracture risk on orthopedic assessment, initiate bone-modifying agents before systemic therapy

---
## References

### Guidelines

[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
  Document: nccn_ovariancancer_v3_2025__v00000000, Page 22
  Content: Survivorship)
Recurrent
diseaset
Hormonal...

[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
  Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 11
  Content: cytoreduction
o Residual ChT toxicity
o The patient’s...

### Literature

[@pubmed | 35096598]
  PMID: 35096598 | Front Oncol | 2021-01-01
  Title: Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.
  DOI: 10.3389/fonc.2021.798173

### Clinical Trials

[@trial | 350]
  Trial ID: 350
  Name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
  Rationale: Patient has recurrent/metastatic ovarian clear cell carcinoma (gynecologic malignancy) with prior standard therapy failure (platinum-resistant after 1L), matching the trial's inclusion for recurrent/metastatic gynecologic malignancies after standard treatment failure.

### Clinical Reports

[@OH2203828 | Genomics]
  Genomics ID: OH2203828 | Date: 2022-04-18
  Content: ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1...

[@20230103|5600862 | LAB]
  LAB ID: 20230103|5600862 | Date: 2023-01-03
  Content: 中性粒细胞% 76.5 % (GRAN) PLT分布宽度 12 % (PDW) 嗜碱性细胞数 0.01 *10^9/L...

```


## PIPELINE FLOW (Mermaid)

```mermaid
flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]
```


## TRACE EVENTS (Structured)

```json
[
  {
    "ts": "2026-01-21T07:12:07.509814",
    "event": "pipeline_start",
    "payload": {
      "visit_time": "2023-01-03 08:53:29.260000",
      "meta_info": "340123197709263626"
    }
  },
  {
    "ts": "2026-01-21T07:12:07.510273",
    "event": "case_fingerprint",
    "payload": {
      "case_fingerprint": "2a31f255c155"
    }
  },
  {
    "ts": "2026-01-21T07:12:07.801476",
    "event": "reports_loaded",
    "payload": {
      "lab_n": 92,
      "img_n": 10,
      "path_n": 0,
      "mut_n": 1,
      "cutoff_dt": "2023-01-04 08:53:29"
    }
  },
  {
    "ts": "2026-01-21T07:12:18.090863",
    "event": "reports_selected",
    "payload": {
      "lab": {
        "chair": [
          "20221229|9703212|2022-12-29",
          "20230103|10100203|2023-01-03",
          "20230103|5600862|2023-01-03"
        ],
        "oncologist": [
          "20221229|9703212|2022-12-29",
          "20230103|10100203|2023-01-03",
          "20230103|5600862|2023-01-03"
        ],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "imaging": {
        "chair": [
          "2022-10-24|MR|2022-10-24",
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ],
        "oncologist": [],
        "radiologist": [
          "2022-10-24|MR|2022-10-24",
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ],
        "pathologist": [],
        "nuclear": [
          "2022-10-24|MR|2022-10-24",
          "2022-12-29|MR|2022-12-29",
          "2022-12-29|CT|2022-12-29"
        ]
      },
      "pathology": {
        "chair": [],
        "oncologist": [],
        "radiologist": [],
        "pathologist": [],
        "nuclear": []
      },
      "mutation": {
        "chair": [
          "OH2203828|2022-04-18"
        ],
        "oncologist": [
          "OH2203828|2022-04-18"
        ],
        "radiologist": [],
        "pathologist": [
          "OH2203828|2022-04-18"
        ],
        "nuclear": []
      }
    }
  },
  {
    "ts": "2026-01-21T07:12:18.096595",
    "event": "rag_key_facts",
    "payload": {
      "facts": "DIAGNOSIS: primary=卵巢癌复发; histology=透明细胞癌; 肠壁全层见高级别腺癌; components=High-grade adenocarcinoma involving full-thickness intestinal wall;Lymph node metastasis (4/15);Peritoneal/rectal/vaginal involvement described\nPATHOLOGY: Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma\nPLATINUM: status=Resistant; pfi_days=56\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=<0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; full_text=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）"
    }
  },
  {
    "ts": "2026-01-21T07:12:46.257035",
    "event": "rag_query",
    "payload": {
      "query": "Recurrent ovarian clear cell carcinoma, platinum-resistant (relapse <6 months post-chemotherapy), with hepatic, pelvic, and possible bone metastases; HRD-negative, BRCA1/2-negative, germline ATM Y316C variant; MSS; Ki-67 60%; histology: clear cell carcinoma"
    }
  },
  {
    "ts": "2026-01-21T07:12:46.257040",
    "event": "rag_hits",
    "payload": {
      "source": "guideline",
      "topk": 5,
      "n": 5
    }
  },
  {
    "ts": "2026-01-21T07:12:46.257042",
    "event": "rag_hits",
    "payload": {
      "source": "pubmed",
      "topk": 5,
      "n": 5
    }
  },
  {
    "ts": "2026-01-21T07:12:46.257044",
    "event": "rag_hits_merged",
    "payload": {
      "n": 10
    }
  },
  {
    "ts": "2026-01-21T07:13:00.679598",
    "event": "mdt_discussion_start",
    "payload": {
      "num_rounds": 2,
      "num_turns": 2
    }
  },
  {
    "ts": "2026-01-21T07:13:00.679673",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "chair",
      "order": 1
    }
  },
  {
    "ts": "2026-01-21T07:13:08.332232",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "chair",
      "chars": 482
    }
  },
  {
    "ts": "2026-01-21T07:13:08.332293",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "oncologist",
      "order": 2
    }
  },
  {
    "ts": "2026-01-21T07:13:15.630544",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "oncologist",
      "chars": 484
    }
  },
  {
    "ts": "2026-01-21T07:13:15.630653",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "radiologist",
      "order": 3
    }
  },
  {
    "ts": "2026-01-21T07:13:22.112890",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "radiologist",
      "chars": 371
    }
  },
  {
    "ts": "2026-01-21T07:13:22.112977",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "pathologist",
      "order": 4
    }
  },
  {
    "ts": "2026-01-21T07:13:29.261824",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "pathologist",
      "chars": 457
    }
  },
  {
    "ts": "2026-01-21T07:13:29.261928",
    "event": "mdt_initial_opinion_role_start",
    "payload": {
      "role": "nuclear",
      "order": 5
    }
  },
  {
    "ts": "2026-01-21T07:13:34.534406",
    "event": "mdt_initial_opinion_role_end",
    "payload": {
      "role": "nuclear",
      "chars": 421
    }
  },
  {
    "ts": "2026-01-21T07:13:50.120505",
    "event": "evidence_tag_warning",
    "payload": {
      "role": "oncologist->chair/turn_1",
      "preview": "Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classific…"
    }
  },
  {
    "ts": "2026-01-21T07:14:30.509872",
    "event": "mdt_discussion_end",
    "payload": {
      "merged_chars": 2007
    }
  },
  {
    "ts": "2026-01-21T07:14:30.511781",
    "event": "trial_matching_start",
    "payload": {
      "trials_json_path": "files/all_trials_filtered.json"
    }
  },
  {
    "ts": "2026-01-21T07:14:38.530678",
    "event": "trial_matching_end",
    "payload": {
      "recommended": true
    }
  },
  {
    "ts": "2026-01-21T07:14:38.530698",
    "event": "final_output_start",
    "payload": {}
  },
  {
    "ts": "2026-01-21T07:14:45.921042",
    "event": "final_output_end",
    "payload": {
      "final_output_chars": 2561
    }
  }
]
```


## INITIAL EXPERT OPINIONS


## chair

```
• **Platinum-resistant** (PFI 56 days) clear cell carcinoma with hepatic/bone metastases; non-platinum regimen indicated [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

• **BRCA1/2 negative, HRD negative** [@OH2203828 | Genomics]; PARPi unlikely beneficial per clear cell carcinoma biology [@pubmed | 35096598]

• **ATM germline variant** detected; clinical significance for targeted therapy uncertain—consider clinical trial enrollment or immunotherapy-based approach
```


## oncologist

```
• Recurrent clear cell carcinoma ~5 months post-platinum; platinum-sensitive relapse warrants platinum-based rechallenge consideration [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]

• ATM germline variant detected, BRCA1/2 negative, HRD negative—limited PARPi benefit expected for this histotype [@OH2203828 | Genomics] [@pubmed | 35096598]

• Hemoglobin 74 g/L indicates moderate anemia requiring correction before systemic therapy initiation [@20230103|5600862 | LAB]
```


## radiologist

```
• Presacral mass enlarged (53×44mm) with sacral/iliac bone involvement; disease progression confirmed [@2022-12-29 | MR]

• Hepatic metastases increased in number/size; splenic infarct possible [@2022-12-29 | CT]

• Imaging shows multi-site progression; assess surgical candidacy per recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
```


## pathologist

```
• Histology confirms ovarian clear cell carcinoma with high-grade features, HNF1B+/NapsinA focal+/WT1-, consistent with diagnosis [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]

• BRCA1/2 negative, HRD negative per NGS; ATM germline variant (p.Y316C) detected—clinical significance uncertain [@OH2203828 | Genomics]

• Clear cell histotype shows low HRR mutation prevalence, limiting PARP inhibitor benefit expectation [@pubmed | 35096598]
```


## nuclear

```
• No PET-CT available; metabolic staging incomplete for assessing recurrence extent or treatment response monitoring.

• CT/MR show progressive hepatic metastases and presacral disease with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].

• PET-CT recommended to evaluate full metabolic burden before considering secondary cytoreduction candidacy [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].
```


## MERGED SUMMARY (Assistant)

```
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit
- MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy
- Bone involvement (sacrum, right iliac) poses fracture risk requiring orthopedic assessment

### Controversies
- **ATM variant actionability**: Clinical significance for targeted therapy remains uncertain; potential role in clinical trial or immunotherapy-based approaches unclear
- **Platinum sensitivity debate resolved**: Consensus reached that PFI 56 days confirms platinum-resistant status requiring non-platinum regimen

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- MSI/TMB testing results to inform checkpoint inhibitor candidacy
- Orthopedic assessment for bone fracture risk

### Working Plan
- **Non-platinum systemic regimen** required given confirmed platinum-resistant status (PFI 56 days)
- **Correct anemia** (Hgb 74 g/L) before initiating systemic therapy; consider transfusion or erythropoietin/iron supplementation
- **Obtain PET-CT** for comprehensive metabolic staging before treatment decisions
- **Consider clinical trial enrollment or immunotherapy-based approach** given BRCA1/2-negative, HRD-negative, limited PARPi benefit
- **Request MSI/TMB testing** to evaluate checkpoint inhibitor candidacy
- **Orthopedic consultation** for bone metastases fracture risk assessment
- **Evaluate secondary cytoreduction candidacy** per ESMO recurrence guidelines
```


## INTERACTION LOG (Round × Turn)

### Round 1

#### Turn 1
- **chair → oncologist:** Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].
- **oncologist → chair:** Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.


## FINAL REFINED PLANS (per Round)

### Round 1


## chair

```
• **Non-platinum regimen required**: PFI 56 days confirms platinum-resistant status; avoid platinum rechallenge [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

• **Correct anemia** (Hgb 74 g/L) [@20230103|5600862 | LAB] before initiating systemic therapy; consider transfusion or erythropoietin

• **Clinical trial/immunotherapy consideration** given BRCA1/2-negative, HRD-negative status [@OH2203828 | Genomics] and limited PARPi benefit in clear cell histology
```


## oncologist

```
• Platinum-resistant disease (PFI 56 days) requires non-platinum systemic regimen per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

• Correct anemia (Hgb 74 g/L) prior to therapy initiation; transfusion or iron supplementation indicated [@20230103|5600862 | LAB]

• HRD-negative, BRCA-negative status limits PARPi benefit; consider clinical trial or immunotherapy-based approach [@OH2203828 | Genomics] [@pubmed | 35096598]
```


## radiologist

```
• Multi-site progression confirmed: presacral mass, hepatic/bone metastases; recommend PET-CT for complete staging [@2022-12-29 | MR] [@2022-12-29 | CT]

• Bone involvement (sacrum, right iliac) warrants orthopedic assessment for fracture risk before therapy initiation

• Secondary cytoreduction candidacy should be evaluated per ESMO recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
```


## pathologist

```
• Confirmed clear cell carcinoma, BRCA1/2 negative, HRD negative; ATM germline variant significance uncertain [@OH2203828 | Genomics]

• Low HRR mutation prevalence in clear cell histotype limits PARPi utility; consider immunotherapy/trial-based approaches [@pubmed | 35096598]

• MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy
```


## nuclear

```
• PET-CT recommended for complete metabolic staging before treatment decisions in recurrent disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].

• Current MR/CT confirm progressive presacral and hepatic metastases with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].

• Metabolic imaging essential to assess full disease burden and monitor non-platinum therapy response.
```


## RAW AGENT LOGS

### chair
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** • **Platinum-resistant** (PFI 56 days) clear cell carcinoma with hepatic/bone metastases; non-platinum regimen indicated [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

• **BRCA1/2 negative, HRD negative** [@OH2203828 | Genomics]; PARPi unlikely beneficial per clear cell carcinoma biology [@pubmed | 35096598]

• **ATM germline variant** detected; clinical significance for targeted therapy uncertain—consider clinical trial enrollment or immunotherapy-based approach
  
  *(2026-01-21T07:13:08.332208)*

- **User:** ROLE: chair. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

Allowed targets: [oncologist,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"oncologist","message":"Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22].","why":"conflict"}]}
  
  *(2026-01-21T07:13:45.840106)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

[RECENT_DELTAS]
[R1T1 DELTA] chair->oncologist(conflict): Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist->chair(conflict): Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist→chair: Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** • **Non-platinum regimen required**: PFI 56 days confirms platinum-resistant status; avoid platinum rechallenge [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

• **Correct anemia** (Hgb 74 g/L) [@20230103|5600862 | LAB] before initiating systemic therapy; consider transfusion or erythropoietin

• **Clinical trial/immunotherapy consideration** given BRCA1/2-negative, HRD-negative status [@OH2203828 | Genomics] and limited PARPi benefit in clear cell histology
  
  *(2026-01-21T07:14:04.628258)*

- **User:** 
As the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.
Based on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.

# MDT DISCUSSION SUMMARY
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit
- MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy
- Bone involvement (sacrum, right iliac) poses fracture risk requiring orthopedic assessment

### Controversies
- **ATM variant actionability**: Clinical significance for targeted therapy remains uncertain; potential role in clinical trial or immunotherapy-based approaches unclear
- **Platinum sensitivity debate resolved**: Consensus reached that PFI 56 days confirms platinum-resistant status requiring non-platinum regimen

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- MSI/TMB testing results to inform checkpoint inhibitor candidacy
- Orthopedic assessment for bone fracture risk

### Working Plan
- **Non-platinum systemic regimen** required given confirmed platinum-resistant status (PFI 56 days)
- **Correct anemia** (Hgb 74 g/L) before initiating systemic therapy; consider transfusion or erythropoietin/iron supplementation
- **Obtain PET-CT** for comprehensive metabolic staging before treatment decisions
- **Consider clinical trial enrollment or immunotherapy-based approach** given BRCA1/2-negative, HRD-negative, limited PARPi benefit
- **Request MSI/TMB testing** to evaluate checkpoint inhibitor candidacy
- **Orthopedic consultation** for bone metastases fracture risk assessment
- **Evaluate secondary cytoreduction candidacy** per ESMO recurrence guidelines

# INITIAL EXPERT OPINIONS
- chair: • **Platinum-resistant** (PFI 56 days) clear cell carcinoma with hepatic/bone metastases; non-platinum regimen indicated [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

• **BRCA1/2 negat
- oncologist: • Recurrent clear cell carcinoma ~5 months post-platinum; platinum-sensitive relapse warrants platinum-based rechallenge consideration [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]

• A
- radiologist: • Presacral mass enlarged (53×44mm) with sacral/iliac bone involvement; disease progression confirmed [@2022-12-29 | MR]

• Hepatic metastases increased in number/size; splenic infarct possible [@2022
- pathologist: • Histology confirms ovarian clear cell carcinoma with high-grade features, HNF1B+/NapsinA focal+/WT1-, consistent with diagnosis [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]

• BR
- nuclear: • No PET-CT available; metabolic staging incomplete for assessing recurrence extent or treatment response monitoring.

• CT/MR show progressive hepatic metastases and presacral disease with bone invol

# DISCUSSION INTERACTIONS
Round 1: R1T1: chair→oncologist: Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 202 | R1T1: oncologist→chair: Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (bi



# FINAL REFINED PLANS (All experts, all rounds)
{
  "Round 1": {
    "chair": "• **Non-platinum regimen required**: PFI 56 days confirms platinum-resistant status; avoid platinum rechallenge [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\n• **Correct anemia** (Hgb 74 g/L) [@20230103|5600862 | LAB] before initiating systemic therapy; consider transfusion or erythropoietin\n\n• **Clinical trial/immunotherapy consideration** given BRCA1/2-negative, HRD-negative status [@OH2203828 | Genomics] and limited PARPi benefit in clear cell histology",
    "oncologist": "• Platinum-resistant disease (PFI 56 days) requires non-platinum systemic regimen per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\n• Correct anemia (Hgb 74 g/L) prior to therapy initiation; transfusion or iron supplementation indicated [@20230103|5600862 | LAB]\n\n• HRD-negative, BRCA-negative status limits PARPi benefit; consider clinical trial or immunotherapy-based approach [@OH2203828 | Genomics] [@pubmed | 35096598]",
    "radiologist": "• Multi-site progression confirmed: presacral mass, hepatic/bone metastases; recommend PET-CT for complete staging [@2022-12-29 | MR] [@2022-12-29 | CT]\n\n• Bone involvement (sacrum, right iliac) warrants orthopedic assessment for fracture risk before therapy initiation\n\n• Secondary cytoreduction candidacy should be evaluated per ESMO recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]",
    "pathologist": "• Confirmed clear cell carcinoma, BRCA1/2 negative, HRD negative; ATM germline variant significance uncertain [@OH2203828 | Genomics]\n\n• Low HRR mutation prevalence in clear cell histotype limits PARPi utility; consider immunotherapy/trial-based approaches [@pubmed | 35096598]\n\n• MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy",
    "nuclear": "• PET-CT recommended for complete metabolic staging before treatment decisions in recurrent disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].\n\n• Current MR/CT confirm progressive presacral and hepatic metastases with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].\n\n• Metabolic imaging essential to assess full disease burden and monitor non-platinum therapy response."
  }
}

# CLINICAL TRIAL RECOMMENDATION (from assistant)
Trial Recommendation:
- id: 350
- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
- Reason: Patient has recurrent/metastatic ovarian clear cell carcinoma (gynecologic malignancy) with prior standard therapy failure (platinum-resistant after 1L), matching the trial's inclusion for recurrent/metastatic gynecologic malignancies after standard treatment failure.
- Missing eligibility confirmations (0-2 items):
  - ECOG performance status confirmation
  - Adequate organ function (hematologic, hepatic, renal) confirmation

STRICT RULES:
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@OH2203828|2022-04-18 | Genomics], [@2022-12-29 | MR], [@2022-12-29 | CT]). Note: Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.
- If a clinical trial has been recommended by the assistant and you judge it appropriate for the patient, mention it naturally within Core Treatment Strategy or Change Triggers and cite it using [@trial | trial_id] format (e.g., [@trial | 350]).
- If experts disagree, pick the safest plan and state the key uncertainty.
- You MUST consider the MDT discussion summary and interactions above when making your decision.

# Response Format
Final Assessment:
<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>

Core Treatment Strategy:
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >
- < ≤20 words concrete decision >

Change Triggers:
- < ≤20 words "if X, then adjust management from A to B" >
- < ≤20 words "if X, then adjust management from A to B" >

  
  **Assistant:** # Final Assessment
Recurrent platinum-resistant (PFI 56 days) ovarian clear cell carcinoma with hepatic, presacral, and bone metastases; BRCA1/2 negative, HRD negative [@OH2203828 | Genomics], limiting PARPi utility; moderate anemia requires correction before systemic therapy.

# Core Treatment Strategy
- **Initiate non-platinum systemic regimen** per platinum-resistant status classification [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]
- **Correct anemia (Hgb 74 g/L)** [@20230103|5600862 | LAB] with transfusion before chemotherapy initiation
- **Obtain PET-CT** for complete metabolic staging to guide treatment planning [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
- **Evaluate clinical trial eligibility** for BL-B01D1 study in recurrent gynecologic malignancies [@trial | 350]; confirm ECOG status and organ function

# Change Triggers
- If MSI-high/TMB-high detected, consider adding checkpoint inhibitor to treatment strategy [@pubmed | 35096598]
- If bone lesions show high fracture risk on orthopedic assessment, initiate bone-modifying agents before systemic therapy
  
  *(2026-01-21T07:14:45.917427)*


### oncologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** • Recurrent clear cell carcinoma ~5 months post-platinum; platinum-sensitive relapse warrants platinum-based rechallenge consideration [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]

• ATM germline variant detected, BRCA1/2 negative, HRD negative—limited PARPi benefit expected for this histotype [@OH2203828 | Genomics] [@pubmed | 35096598]

• Hemoglobin 74 g/L indicates moderate anemia requiring correction before systemic therapy initiation [@20230103|5600862 | LAB]
  
  *(2026-01-21T07:13:15.630484)*

- **User:** ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

Allowed targets: [chair,radiologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"yes","messages":[{"target":"chair","message":"Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.","why":"conflict"}]}
  
  *(2026-01-21T07:13:50.120362)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

[RECENT_DELTAS]
[R1T1 DELTA] chair->oncologist(conflict): Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist->chair(conflict): Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist→chair: Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** • Platinum-resistant disease (PFI 56 days) requires non-platinum systemic regimen per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]

• Correct anemia (Hgb 74 g/L) prior to therapy initiation; transfusion or iron supplementation indicated [@20230103|5600862 | LAB]

• HRD-negative, BRCA-negative status limits PARPi benefit; consider clinical trial or immunotherapy-based approach [@OH2203828 | Genomics] [@pubmed | 35096598]
  
  *(2026-01-21T07:14:09.460018)*


### radiologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** • Presacral mass enlarged (53×44mm) with sacral/iliac bone involvement; disease progression confirmed [@2022-12-29 | MR]

• Hepatic metastases increased in number/size; splenic infarct possible [@2022-12-29 | CT]

• Imaging shows multi-site progression; assess surgical candidacy per recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
  
  *(2026-01-21T07:13:22.112859)*

- **User:** ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

Allowed targets: [chair,oncologist,pathologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"no","messages":[]}
  
  *(2026-01-21T07:13:52.902809)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

[RECENT_DELTAS]
[R1T1 DELTA] chair->oncologist(conflict): Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist->chair(conflict): Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist→chair: Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** • Multi-site progression confirmed: presacral mass, hepatic/bone metastases; recommend PET-CT for complete staging [@2022-12-29 | MR] [@2022-12-29 | CT]

• Bone involvement (sacrum, right iliac) warrants orthopedic assessment for fracture risk before therapy initiation

• Secondary cytoreduction candidacy should be evaluated per ESMO recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]
  
  *(2026-01-21T07:14:14.305067)*


### pathologist
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** • Histology confirms ovarian clear cell carcinoma with high-grade features, HNF1B+/NapsinA focal+/WT1-, consistent with diagnosis [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]

• BRCA1/2 negative, HRD negative per NGS; ATM germline variant (p.Y316C) detected—clinical significance uncertain [@OH2203828 | Genomics]

• Clear cell histotype shows low HRR mutation prevalence, limiting PARP inhibitor benefit expectation [@pubmed | 35096598]
  
  *(2026-01-21T07:13:29.261781)*

- **User:** ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

Allowed targets: [chair,oncologist,radiologist,nuclear]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"no","messages":[]}
  
  *(2026-01-21T07:13:56.717269)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

[RECENT_DELTAS]
[R1T1 DELTA] chair->oncologist(conflict): Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist->chair(conflict): Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist→chair: Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** • Confirmed clear cell carcinoma, BRCA1/2 negative, HRD negative; ATM germline variant significance uncertain [@OH2203828 | Genomics]

• Low HRR mutation prevalence in clear cell histotype limits PARPi utility; consider immunotherapy/trial-based approaches [@pubmed | 35096598]

• MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy
  
  *(2026-01-21T07:14:19.029171)*


### nuclear
- **User:** Give INITIAL opinion (use ONLY your system-provided patient facts).
Return up to 3 bullets, each ≤20 words.
If key data missing, say exactly what needs updating.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
For clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].
  
  **Assistant:** • No PET-CT available; metabolic staging incomplete for assessing recurrence extent or treatment response monitoring.

• CT/MR show progressive hepatic metastases and presacral disease with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].

• PET-CT recommended to evaluate full metabolic burden before considering secondary cytoreduction candidacy [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].
  
  *(2026-01-21T07:13:34.534378)*

- **User:** ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000
Default is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.

CONTEXT (latest):
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

Allowed targets: [chair,oncologist,radiologist,pathologist]

EVIDENCE TAGS (if your message references evidence):
- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].

Return ONE-LINE JSON only:{"speak":"yes/no","messages":[{"target":"<role>","message":"<1-2 sentences with evidence tags if applicable>","why":"conflict|safety|missing|new"}]}
  
  **Assistant:** {"speak":"no","messages":[]}
  
  *(2026-01-21T07:13:58.400567)*

- **User:** Given MDT context:
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

[RECENT_DELTAS]
[R1T1 DELTA] chair->oncologist(conflict): Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist->chair(conflict): Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

DISCUSSION HISTORY (this round):
Turn 1: chair→oncologist: Please clarify platinum-free interval calculation: last platinum 2022-08-17, biochemical relapse 2022-10-12 = 56 days, confirming platinum-resistant status per NCCN criteria (<6 months) [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]. | oncologist→chair: Clarification on platinum-free interval: last platinum 2022-08-17, relapse documented 2022-10-12 (biochemical) gives ~56 days—agree platinum-resistant classification; my initial statement was imprecise.

Provide FINAL refined plan based on the above context and discussions.
Up to 3 bullets, each ≤20 words.
Any factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.
At least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].
If you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].
If discussions mentioned specific evidence, you may reference it with appropriate tags.
  
  **Assistant:** • PET-CT recommended for complete metabolic staging before treatment decisions in recurrent disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].

• Current MR/CT confirm progressive presacral and hepatic metastases with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].

• Metabolic imaging essential to assess full disease burden and monitor non-platinum therapy response.
  
  *(2026-01-21T07:14:23.199638)*


### assistant
- **User:** Summarize expert opinions concisely for MDT.
{"chair":"• **Platinum-resistant** (PFI 56 days) clear cell carcinoma with hepatic/bone metastases; non-platinum regimen indicated [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\n• **BRCA1/2 negative, HRD negative** [@OH2203828 | Genomics]; PARPi unlikely beneficial per clear cell carcinoma biology [@pubmed | 35096598]\n\n• **ATM germline variant** detected; clinical significance for targeted therapy uncertain—consider clinical trial enrollment or immunotherapy-based approach","oncologist":"• Recurrent clear cell carcinoma ~5 months post-platinum; platinum-sensitive relapse warrants platinum-based rechallenge consideration [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\n\n• ATM germline variant detected, BRCA1/2 negative, HRD negative—limited PARPi benefit expected for this histotype [@OH2203828 | Genomics] [@pubmed | 35096598]\n\n• Hemoglobin 74 g/L indicates moderate anemia requiring correction before systemic therapy initiation [@20230103|5600862 | LAB]","radiologist":"• Presacral mass enlarged (53×44mm) with sacral/iliac bone involvement; disease progression confirmed [@2022-12-29 | MR]\n\n• Hepatic metastases increased in number/size; splenic infarct possible [@2022-12-29 | CT]\n\n• Imaging shows multi-site progression; assess surgical candidacy per recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]","pathologist":"• Histology confirms ovarian clear cell carcinoma with high-grade features, HNF1B+/NapsinA focal+/WT1-, consistent with diagnosis [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]\n\n• BRCA1/2 negative, HRD negative per NGS; ATM germline variant (p.Y316C) detected—clinical significance uncertain [@OH2203828 | Genomics]\n\n• Clear cell histotype shows low HRR mutation prevalence, limiting PARP inhibitor benefit expectation [@pubmed | 35096598]","nuclear":"• No PET-CT available; metabolic staging incomplete for assessing recurrence extent or treatment response monitoring.\n\n• CT/MR show progressive hepatic metastases and presacral disease with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].\n\n• PET-CT recommended to evaluate full metabolic burden before considering secondary cytoreduction candidacy [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]."}

Output:
Key Knowledge:
- ...
Controversies:
- ...
Missing Info:
- ...
Working Plan:
- ...
  
  **Assistant:** ## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines
  
  *(2026-01-21T07:13:41.840869)*

- **User:** You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.

CURRENT_MDT_GLOBAL_KNOWLEDGE:
[MDT_GLOBAL_KNOWLEDGE]
## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit

### Controversies
- **Platinum sensitivity status**: Chair classifies as platinum-resistant (PFI 56 days) requiring non-platinum regimen; Oncologist suggests platinum-sensitive relapse warrants rechallenge consideration
- **ATM variant actionability**: Clinical significance for targeted therapy uncertain; potential role in clinical trial or immunotherapy-based approaches unclear

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- Clarification of exact platinum-free interval calculation

### Working Plan
- Non-platinum systemic regimen given platinum-resistant status
- Correct anemia before initiating systemic therapy
- Consider clinical trial enrollment or immunotherapy-based approach
- Obtain PET-CT for comprehensive disease staging
- Evaluate secondary cytoreduction candidacy per guidelines

ROUND_1_FINAL_PLANS_JSON:
{"chair":"• **Non-platinum regimen required**: PFI 56 days confirms platinum-resistant status; avoid platinum rechallenge [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\n• **Correct anemia** (Hgb 74 g/L) [@20230103|5600862 | LAB] before initiating systemic therapy; consider transfusion or erythropoietin\n\n• **Clinical trial/immunotherapy consideration** given BRCA1/2-negative, HRD-negative status [@OH2203828 | Genomics] and limited PARPi benefit in clear cell histology","oncologist":"• Platinum-resistant disease (PFI 56 days) requires non-platinum systemic regimen per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 22]\n\n• Correct anemia (Hgb 74 g/L) prior to therapy initiation; transfusion or iron supplementation indicated [@20230103|5600862 | LAB]\n\n• HRD-negative, BRCA-negative status limits PARPi benefit; consider clinical trial or immunotherapy-based approach [@OH2203828 | Genomics] [@pubmed | 35096598]","radiologist":"• Multi-site progression confirmed: presacral mass, hepatic/bone metastases; recommend PET-CT for complete staging [@2022-12-29 | MR] [@2022-12-29 | CT]\n\n• Bone involvement (sacrum, right iliac) warrants orthopedic assessment for fracture risk before therapy initiation\n\n• Secondary cytoreduction candidacy should be evaluated per ESMO recurrence guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11]","pathologist":"• Confirmed clear cell carcinoma, BRCA1/2 negative, HRD negative; ATM germline variant significance uncertain [@OH2203828 | Genomics]\n\n• Low HRR mutation prevalence in clear cell histotype limits PARPi utility; consider immunotherapy/trial-based approaches [@pubmed | 35096598]\n\n• MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy","nuclear":"• PET-CT recommended for complete metabolic staging before treatment decisions in recurrent disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 11].\n\n• Current MR/CT confirm progressive presacral and hepatic metastases with bone involvement [@2022-12-29 | MR] [@2022-12-29 | CT].\n\n• Metabolic imaging essential to assess full disease burden and monitor non-platinum therapy response."}
  
  **Assistant:** ## MDT Summary

### Key Knowledge
- Platinum-resistant (PFI 56 days) recurrent ovarian clear cell carcinoma with hepatic and bone metastases
- BRCA1/2 negative, HRD negative; ATM germline variant (p.Y316C) of uncertain significance
- Progressive disease on imaging: enlarged presacral mass (53×44mm) with sacral/iliac involvement, increased hepatic metastases
- Moderate anemia (Hgb 74 g/L) requiring correction before therapy
- Clear cell histotype has low HRR mutation prevalence, limiting PARPi benefit
- MMR status intact (MLH1/MSH2/MSH6/PMS2 all positive); MSI/TMB testing could inform checkpoint inhibitor candidacy
- Bone involvement (sacrum, right iliac) poses fracture risk requiring orthopedic assessment

### Controversies
- **ATM variant actionability**: Clinical significance for targeted therapy remains uncertain; potential role in clinical trial or immunotherapy-based approaches unclear
- **Platinum sensitivity debate resolved**: Consensus reached that PFI 56 days confirms platinum-resistant status requiring non-platinum regimen

### Missing Info
- PET-CT for complete metabolic staging and treatment response monitoring
- Surgical candidacy assessment for secondary cytoreduction
- MSI/TMB testing results to inform checkpoint inhibitor candidacy
- Orthopedic assessment for bone fracture risk

### Working Plan
- **Non-platinum systemic regimen** required given confirmed platinum-resistant status (PFI 56 days)
- **Correct anemia** (Hgb 74 g/L) before initiating systemic therapy; consider transfusion or erythropoietin/iron supplementation
- **Obtain PET-CT** for comprehensive metabolic staging before treatment decisions
- **Consider clinical trial enrollment or immunotherapy-based approach** given BRCA1/2-negative, HRD-negative, limited PARPi benefit
- **Request MSI/TMB testing** to evaluate checkpoint inhibitor candidacy
- **Orthopedic consultation** for bone metastases fracture risk assessment
- **Evaluate secondary cytoreduction candidacy** per ESMO recurrence guidelines
  
  *(2026-01-21T07:14:30.509192)*


### trial_selector
- **User:** You are an MDT assistant for gynecologic oncology clinical trial matching.

CRITICAL BEHAVIOR:
- You MUST NOT ask the user any questions.
- You MUST NOT request additional information.
- You MUST NOT output anything except the required template.
- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.
- If eligibility is unclear due to missing key facts, you MUST output None.

PATIENT CASE (facts only; do not infer):
# ORIGINAL CASE JSON
{"CASE_CORE":{"ADJUVANT_TREATMENT":{"cycles_or_courses":"6","given":"Yes","regimens":["白紫+卡铂"]},"BIOMARKERS":{"AFP":"<0.91 ng/ml (2022-10-12)","CA125":"933.00 U/ml (2022-12-29)","HER2":"Unknown","MSI":"Unknown","PDL1_CPS":"Unknown","TMB":"Unknown"},"BRCA1":"Unknown","BRCA2":"Unknown","CURRENT_STATUS":"Recurrent ovarian clear cell carcinoma with metastatic disease (liver, presacral/sacrum, right iliac bone) documented on imaging","DIAGNOSIS":{"components":["High-grade adenocarcinoma involving full-thickness intestinal wall","Lymph node metastasis (4/15)","Peritoneal/rectal/vaginal involvement described"],"histology":"透明细胞癌; 肠壁全层见高级别腺癌","laterality":"Unknown","primary":"卵巢癌复发","site":"Ovary"},"HRD":"Unknown","INITIAL_TREATMENT":"Unknown","LINE_OF_THERAPY":[{"cycles":"6","end_date":"2022-08-17","intent":"Unknown","line":"1L","regimen":"白紫+卡铂","start_date":"Unknown"}],"MAINTENANCE":"Unknown","MAINTENANCE_DETAIL":{"end_date":"Unknown","given":"Unknown","regimens":[],"start_date":"Unknown"},"NEOADJUVANT":"Unknown","PFI_days":"56","PLATINUM_HISTORY":[{"PFI_days":"56","end_date":"2022-08-17","evidence":"Rise in CA125/CA19-9 on 2022-10-12","evidence_type":"Biochemical","first_relapse_date":"2022-10-12","line":"1L","start_date":"Unknown","status":"Resistant"}],"PLATINUM_PFI_CURRENT":"56","PLATINUM_STATUS":"Resistant","PLATINUM_STATUS_CURRENT":"Resistant","RELAPSE":"Yes","RELAPSE_DATE":{"date":"2022-10-12","evidence":"Elevated CA125 and CA19-9 on 2022-10-12; imaging (MRI 2022-10-24, CT 2022-10-25) supports recurrence","type":"Biochemical"},"SCENE":"Platinum_resistant_relapse","STAGE":{"stage_basis":"Unknown","stage_system":"Unknown","stage_text":"Unknown"},"SURGERY_DONE":{"date":"2022-03-28","performed":"Yes","procedure":"Tumor debulking + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair"},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]},"VISIT_DATE":"2023-01-03","first_relapse_date":"2022-10-12","last_platinum_end_date":"2022-08-17"},"LAB_TRENDS":{"labs":[{"analyte":"CA125","history":[{"date":"2022-08-15","flag":"Unknown","value":"14.90"},{"date":"2022-10-12","flag":"↑","value":"89.60"},{"date":"2022-11-17","flag":"↑","value":"403"},{"date":"2022-12-29","flag":"↑","value":"933.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"933.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"CA19-9","history":[{"date":"2022-08-15","flag":"Unknown","value":"7.16"},{"date":"2022-10-12","flag":"↑","value":"77.20"},{"date":"2022-12-29","flag":"↑","value":"229.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"229.00"},"reference_range":"Unknown","unit":"U/ml"},{"analyte":"HE4","history":[{"date":"2022-08-15","flag":"↑","value":"87.90"},{"date":"2022-10-12","flag":"Unknown","value":"59.70"},{"date":"2022-12-29","flag":"↑","value":"111.00"}],"latest":{"date":"2022-12-29","flag":"↑","value":"111.00"},"reference_range":"Unknown","unit":"pmol/L"},{"analyte":"AFP","history":[{"date":"2022-10-12","flag":"Unknown","value":"<0.91"}],"latest":{"date":"2022-10-12","flag":"Unknown","value":"<0.91"},"reference_range":"Unknown","unit":"ng/ml"}],"milestones":[{"date":"2022-03-28","description":"Primary cytoreductive surgery performed","type":"Surgery"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂","type":"ChemoEnd"},{"date":"2022-10-12","description":"Biochemical relapse with rising tumor markers","type":"Relapse"}]},"MED_ONC":{"current_regimen":{"cycle_info":"6 cycles of 白紫+卡铂, last 2022-08-17","last_admin_date":"2022-08-17","name":"Unknown"},"genetic_testing":{"germline":[],"somatic":[]},"monitoring_points":[],"planned_next_regimen":"Unknown","prior_systemic_therapies":["白紫+卡铂"]},"NUC_MED":{"studies":[]},"PATHOLOGY":{"specimens":[{"components":["Tumor size ~7x4x2.5 cm","Bilateral margins negative","Pericolic lymph nodes 4/15 positive","One tumor nodule (posterior bladder)"],"date":"2022-03-28","diagnosis":"Consider ovarian clear cell carcinoma involvement; full-thickness intestinal wall high-grade adenocarcinoma","grade":"High-grade","ihc":[{"marker":"MLH1","result":"+"},{"marker":"MSH6","result":"+"},{"marker":"MSH2","result":"+"},{"marker":"PMS2","result":"+"},{"marker":"ER","result":"partial+"},{"marker":"PR","result":"few weak+"},{"marker":"P53","result":"+/-"},{"marker":"WT1","result":"-"},{"marker":"Ki-67","result":"60%+"},{"marker":"HNF1B","result":"+"},{"marker":"NapsinA","result":"focal+"},{"marker":"P16","result":"+"},{"marker":"PAX8","result":"+"},{"marker":"SALL4","result":"-"},{"marker":"ZBTB16","result":"-"}],"involvement_sites":["Rectosigmoid colon","Left retroperitoneum","Vagina","Pericolic lymph nodes","Posterior bladder nodule"],"laterality":"Unknown","molecular":[],"raw_text":"卵巢恶性肿瘤：卵巢癌复发：术前CA125 45.7 CA199 161 HE4 562 2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）","sample_type":"Surgical resection","site":"Partial rectosigmoid + left retroperitoneal tumor + partial vagina","tumor_size":"7 x 4 x 2.5 cm","uncertainty_or_missing":["BRCA/HRD testing not reported"]}]},"RADIOLOGY":{"next_imaging_plan":{"modality":"Unknown","timing":"Unknown"},"studies":[{"anatomic_sites":["Pelvis"],"date":"2022-10-24","findings":["Postoperative pelvis with presacral mass; pelvic mesenteric multiple enhancing small nodules"],"impression":"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules likely metastases","modality":"MRI","trend_vs_prior":"Unknown"},{"anatomic_sites":["Liver"],"date":"2022-10-25","findings":["Multiple intrahepatic nodules, some new compared to prior"],"impression":"Probable metastases in liver","modality":"CT","trend_vs_prior":"Worse"},{"anatomic_sites":["Pelvis; sacrum; right iliac bone"],"date":"2022-12-30","findings":["Presacral lesion increased in size and heterogeneous enhancement; right iliac bone new enhancing nodule; pelvic mesenteric nodules similar"],"impression":"Progression of presacral disease with possible sacral and iliac bone involvement; peritoneal metastases possible","modality":"MRI","trend_vs_prior":"Worse"},{"anatomic_sites":["Liver; spleen"],"date":"2022-12-30","findings":["Multiple hepatic metastatic nodules increased in number and size; splenic patchy shadow suggesting possible infarct"],"impression":"Progression of hepatic metastases","modality":"CT","trend_vs_prior":"Worse"}]},"TIMELINE":{"constraints":{"max_events":30,"min_events":3,"must_include":["first diagnostic imaging or pathology confirmation (if available)"],"ordering_rules":{"prioritize_last_event":true}},"events":[{"date":"2022-03-28","description":"Cytoreductive surgery including partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair","event_type":"Surgery","key_result":"Tumor ~7x4x2.5 cm; full-thickness intestinal wall high-grade adenocarcinoma; consider ovarian clear cell carcinoma; 4/15 nodes positive","regimen_or_test":"Surgical resection"},{"date":"2022-08-17","description":"Completed 6 cycles of 白紫+卡铂 chemotherapy, last given 2022-08-17","event_type":"Chemo","key_result":"Post-chemo tumor markers reduced on 2022-08-15","regimen_or_test":"白紫+卡铂"},{"date":"2022-10-12","description":"Rising tumor markers indicating recurrence","event_type":"Lab","key_result":"CA19-9 77.20 U/ml; CA125 89.60 U/ml","regimen_or_test":"Tumor markers"},{"date":"2022-10-24","description":"Pelvic MRI shows presacral mass and pelvic mesenteric nodules; consider recurrence with sacral involvement","event_type":"Imaging","key_result":"Presacral lesion and pelvic mesenteric nodules, possible metastases","regimen_or_test":"MRI pelvis"},{"date":"2022-10-25","description":"CT shows multiple liver nodules, some new compared to prior","event_type":"Imaging","key_result":"Multiple hepatic metastatic nodules","regimen_or_test":"CT abdomen"},{"date":"2022-12-29","description":"Markedly elevated tumor markers consistent with progression","event_type":"Lab","key_result":"CA125 933.00 U/ml; CA19-9 229.00 U/ml; HE4 111.00 pmol/L","regimen_or_test":"Tumor markers"},{"date":"2022-12-30","description":"MRI/CT show increased presacral lesion, new right iliac bone nodule, increased hepatic metastases","event_type":"Imaging","key_result":"Progression of pelvic and hepatic metastatic disease","regimen_or_test":"MRI pelvis; CT abdomen"}]}}

# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)
⚠️ COMPREHENSIVE NGS PANEL (~20,000 genes) - INTERPRETATION RULES:
• '未检出' (not detected) = NO pathogenic mutation found
• '（视为阴性）' (considered negative) = NO pathogenic mutation found
• '阴性' (negative) = negative result
• Genes with specific variants (e.g., 'NM_xxx:exon:c.xxx:p.xxx') = POSITIVE mutation
• If a gene is NOT mentioned, it means NO pathogenic mutation (comprehensive panel)

## Mutation Report 1 (ID: OH2203828, Date: 2022-04-18)
ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）


AVAILABLE TRIALS (compact; use id/name exactly as shown):
[
  {
    "id": "345",
    "name": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "2、3、4L",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、HER2 表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "王 涛"
    ],
    "phones": [
      "18721569326"
    ],
    "_raw": {
      "id": "345",
      "项目名称": " 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "李佳佳",
      "试验治疗/用药": "JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2、3、4L",
      "入组排除标准": "1、HER2 表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "王 涛"
      ],
      "联系电话": [
        "18721569326"
      ]
    }
  },
  {
    "id": "346",
    "name": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "朱 俊",
    "sponsor": "阿斯利康投资（中国）有限公司",
    "lead_or_participation": "牵头",
    "treatment": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\n\n2、经标准治疗失败、不能耐受标准治疗\n\n或缺乏有效治疗手段的受试者；",
    "key_exclusion": "",
    "contacts": [
      "江文燕"
    ],
    "phones": [
      "15664735519"
    ],
    "_raw": {
      "id": "346",
      "项目名称": "一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)",
      "医生": "朱 俊",
      "试验治疗/用药": "Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "II期",
      "申请单位": "阿斯利康投资（中国）有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\r\n2、经标准治疗失败、不能耐受标准治疗<br />\r\n或缺乏有效治疗手段的受试者；<br />",
      "联系人": [
        "江文燕"
      ],
      "联系电话": [
        "15664735519"
      ]
    }
  },
  {
    "id": "348",
    "name": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
    "phase": "I期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
    "sponsor": " 上海美雅珂生物技术有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
    "key_inclusion": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
    "key_exclusion": "",
    "contacts": [
      "杨 珂"
    ],
    "phones": [
      "17774582517"
    ],
    "_raw": {
      "id": "348",
      "项目名称": "一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究",
      "医生": "郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳",
      "试验治疗/用药": "MRG004A（ADC，靶向组织因子（tissue factor，TF））",
      "期别": "I期",
      "申请单位": " 上海美雅珂生物技术有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。",
      "联系人": [
        "杨 珂"
      ],
      "联系电话": [
        "17774582517"
      ]
    }
  },
  {
    "id": "350",
    "name": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
    "phase": "Ⅰb/Ⅱ 期",
    "conditions": null,
    "line_of_therapy": "2L、3L",
    "biomarker": null,
    "doctor": "吴 勇、刘汝娇 、高水平",
    "sponsor": "成都百利多特生物药业有限责任公司",
    "lead_or_participation": "牵头",
    "treatment": "单臂研究\n\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
    "key_exclusion": "",
    "contacts": [
      "李 想"
    ],
    "phones": [
      "17703993082"
    ],
    "_raw": {
      "id": "350",
      "项目名称": "评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究",
      "医生": "吴 勇、刘汝娇 、高水平",
      "试验治疗/用药": "单臂研究<br />\r\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）<br />",
      "期别": "Ⅰb/Ⅱ 期",
      "申请单位": "成都百利多特生物药业有限责任公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2L、3L",
      "入组排除标准": "1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤",
      "联系人": [
        "李 想"
      ],
      "联系电话": [
        "17703993082"
      ]
    }
  },
  {
    "id": "351",
    "name": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳、刘汝娇",
    "sponsor": "西藏海思科制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
    "key_inclusion": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
    "key_exclusion": "",
    "contacts": [
      "张倩野"
    ],
    "phones": [
      "18627004197"
    ],
    "_raw": {
      "id": "351",
      "项目名称": " 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究",
      "医生": "李佳佳、刘汝娇",
      "试验治疗/用药": "HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）",
      "期别": "Ⅰ期",
      "申请单位": "西藏海思科制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；",
      "联系人": [
        "张倩野"
      ],
      "联系电话": [
        "18627004197"
      ]
    }
  },
  {
    "id": "353",
    "name": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "刘汝娇",
    "sponsor": " 石药集团中奇制药技术（石家庄）有限公司",
    "lead_or_participation": "参与（天津市肿瘤医院 郝继辉）",
    "treatment": "注射用西罗莫司（白蛋白结合型）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "刘 涵"
    ],
    "phones": [
      "19109628595"
    ],
    "_raw": {
      "id": "353",
      "项目名称": "在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究",
      "医生": "刘汝娇",
      "试验治疗/用药": "注射用西罗莫司（白蛋白结合型）",
      "期别": "Ⅰ期",
      "申请单位": " 石药集团中奇制药技术（石家庄）有限公司",
      "牵头/参与": "参与（天津市肿瘤医院 郝继辉）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "刘 涵"
      ],
      "联系电话": [
        "19109628595"
      ]
    }
  },
  {
    "id": "354",
    "name": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "吴 勇",
    "sponsor": " 浙江道尔生物科技有限公司",
    "lead_or_participation": "参与（组长单位：上海市肺科医院）",
    "treatment": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
    "key_inclusion": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗\n\n2、HPV 16+",
    "key_exclusion": "",
    "contacts": [
      "浦东/郭 伟 、徐汇/江文艳"
    ],
    "phones": [
      "13156793722、15664735519"
    ],
    "_raw": {
      "id": "354",
      "项目名称": "一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究",
      "医生": "吴 勇",
      "试验治疗/用药": "注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）",
      "期别": "Ⅰ期",
      "申请单位": " 浙江道尔生物科技有限公司",
      "牵头/参与": "参与（组长单位：上海市肺科医院）",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗<br />\r\n2、HPV 16+<br />",
      "联系人": [
        "浦东/郭 伟 、徐汇/江文艳"
      ],
      "联系电话": [
        "13156793722、15664735519"
      ]
    }
  },
  {
    "id": "358",
    "name": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": "2-3线",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳",
    "sponsor": "江苏康宁杰瑞生物制药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "徐汇/牛紫嫣 浦东/刘雅琦"
    ],
    "phones": [
      "15638299516 18636833967 "
    ],
    "_raw": {
      "id": "358",
      "项目名称": "评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究",
      "医生": "张 剑 、李佳佳",
      "试验治疗/用药": "JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）",
      "期别": "Ⅰ期",
      "申请单位": "江苏康宁杰瑞生物制药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": "2-3线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者",
      "联系人": [
        "徐汇/牛紫嫣 浦东/刘雅琦"
      ],
      "联系电话": [
        "15638299516 18636833967 "
      ]
    }
  },
  {
    "id": "359",
    "name": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
    "phase": "Ⅰ期",
    "conditions": null,
    "line_of_therapy": ">2L",
    "biomarker": null,
    "doctor": "张 剑 、李佳佳 、刘汝娇、 高水平",
    "sponsor": "苏州盛迪亚生物医药有限公司",
    "lead_or_participation": "牵头",
    "treatment": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
    "key_inclusion": "1、组织学确诊的子宫颈癌；\n\n2、标准治疗失败或无标准治疗患者",
    "key_exclusion": "",
    "contacts": [
      "黄洋洋"
    ],
    "phones": [
      "13226861415"
    ],
    "_raw": {
      "id": "359",
      "项目名称": "SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究",
      "医生": "张 剑 、李佳佳 、刘汝娇、 高水平",
      "试验治疗/用药": "SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）",
      "期别": "Ⅰ期",
      "申请单位": "苏州盛迪亚生物医药有限公司",
      "牵头/参与": "牵头",
      "目标受试者治疗线数": ">2L",
      "入组排除标准": "1、组织学确诊的子宫颈癌；<br />\r\n2、标准治疗失败或无标准治疗患者<br />",
      "联系人": [
        "黄洋洋"
      ],
      "联系电话": [
        "13226861415"
      ]
    }
  },
  {
    "id": "361",
    "name": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
    "phase": "II期",
    "conditions": null,
    "line_of_therapy": "＞1线",
    "biomarker": null,
    "doctor": "李佳佳",
    "sponsor": "Bayer Consumer Care AG",
    "lead_or_participation": "参与",
    "treatment": "单臂研究\n\nBAY 2927088（TKI，靶向HER2）",
    "key_inclusion": "1、标准治疗失败或无标准治疗患者；\n\n2、HER2激活突变（本院或认证的机构）；\n\n3、需提供肿瘤组织切片。",
    "key_exclusion": "",
    "contacts": [
      "李金山"
    ],
    "phones": [
      "18893190113 "
    ],
    "_raw": {
      "id": "361",
      "项目名称": "一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究",
      "医生": "李佳佳",
      "试验治疗/用药": "单臂研究<br />\r\nBAY 2927088（TKI，靶向HER2）<br />",
      "期别": "II期",
      "申请单位": "Bayer Consumer Care AG",
      "牵头/参与": "参与",
      "目标受试者治疗线数": "＞1线",
      "入组排除标准": "1、标准治疗失败或无标准治疗患者；<br />\r\n2、HER2激活突变（本院或认证的机构）；<br />\r\n3、需提供肿瘤组织切片。<br />",
      "联系人": [
        "李金山"
      ],
      "联系电话": [
        "18893190113 "
      ]
    }
  }
]

DECISION RULE (be conservative):
Recommend ONE trial ONLY IF ALL are true:
1) Cancer type / primary site clearly matches.
2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).
3) Required biomarker/subtype is explicitly present in case text (if trial requires it).
4) No more than 2 critical eligibility confirmations remain.

If ANY of the above is not satisfied -> output None.

OUTPUT TEMPLATE (EXACT; no extra text):

Trial Recommendation:
- id: <trial id or None>
- name: <trial name or None>
- Reason: <1 short sentence>
- Missing eligibility confirmations (0-2 items):
  - item1 (or "None")
  - item2
  
  **Assistant:** Trial Recommendation:
- id: 350
- name: 评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究
- Reason: Patient has recurrent/metastatic ovarian clear cell carcinoma (gynecologic malignancy) with prior standard therapy failure (platinum-resistant after 1L), matching the trial's inclusion for recurrent/metastatic gynecologic malignancies after standard treatment failure.
- Missing eligibility confirmations (0-2 items):
  - ECOG performance status confirmation
  - Adequate organ function (hematologic, hepatic, renal) confirmation
  
  *(2026-01-21T07:14:38.530609)*

